Exon 20 Insertion Mutant EGFR-Based Detection and Monitoring Systems

Publication ID: 24-11857513_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Exon 20 Insertion Mutant EGFR-Based Detection and Monitoring Systems,” Published Technical Disclosure No. 24-11857513_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857513_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,513.

Summary of the Inventive Concept

The inventive concept applies the core technology of selective inhibitors of exon 20 insertion mutant EGFR to develop innovative detection and monitoring systems for various industries, including wildfire detection, water quality monitoring, invasive species tracking, agricultural pest control, and neurological disorder diagnosis.

Background and Problem Solved

The original patent focused on antitumor agents for treating cancers with EGFR having exon 20 insertion mutations. However, the detection and monitoring of such mutations have broader applications beyond cancer treatment. The new inventive concept addresses the need for efficient and accurate detection methods in various fields, leveraging the core technology of the original patent.

Detailed Description of the Inventive Concept

The inventive concept encompasses a range of systems and methods that utilize exon 20 insertion mutant EGFR-based detection methods. For instance, a wildfire detection system can employ sensors to detect EGFR having exon 20 insertion mutations in environmental samples, triggering alerts to firefighters. Similarly, a water quality monitoring system can detect EGFR mutations in water samples to generate reports on water quality. The inventive concept also extends to invasive species tracking, agricultural pest control, and neurological disorder diagnosis, where the detection of EGFR mutations enables targeted interventions and treatments.

Novelty and Inventive Step

The new claims introduce novel applications of exon 20 insertion mutant EGFR-based detection methods, moving beyond cancer treatment to address pressing issues in various industries. The inventive step lies in the recognition of the broader potential of this technology and its adaptation to new fields, resulting in innovative solutions that were not obvious from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the development of portable detection devices, integration with existing monitoring systems, or the use of machine learning algorithms to enhance detection accuracy. Variations of the inventive concept could also explore the application of exon 20 insertion mutant EGFR-based detection methods to other fields, such as environmental monitoring or forensic analysis.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential across multiple industries, including environmental monitoring, agriculture, and healthcare. The market for such detection and monitoring systems is substantial, driven by the need for efficient and accurate solutions to pressing problems in these fields. The inventive concept offers a unique value proposition, enabling the development of innovative products and services that can address these needs and create new business opportunities.

CPC Classifications

SectionClassGroup
A A61 A61K31/519
A A61 A61P35/00

Field of Art

Molecular biology, oncology, and diagnostic technologies with a focus on genetic mutation detection and targeted therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology, biotechnology, or biomedical engineering, possessing expertise in genetic mutation analysis, diagnostic sensor technologies, and interdisciplinary application of molecular detection methods

Obviousness Rationale

A person having ordinary skill in the art would recognize the fundamental principle of EGFR mutation detection as a versatile diagnostic technique that could be readily adapted to multiple domains beyond cancer treatment. The source patent's core technology of detecting and targeting exon 20 insertion mutations provides a clear technological framework that can be systematically extended to other detection and monitoring applications. The PTD's variations represent predictable extrapolations of the original detection methodology using standard sensor and diagnostic technologies.

Obvious Combinations & Variations

Source Patent Element
Detection method for EGFR mutations with specific focus on exon 20 insertion variants
PTD Variation
Applying the detection methodology to environmental monitoring, wildfire detection, and species tracking
Obviousness Reasoning
A PHOSITA would recognize that mutation detection principles are transferable across domains using known sensor and diagnostic technologies, representing a routine design adaptation
Source Patent Element
Diagnostic approach for identifying specific genetic mutations in lung tumor samples
PTD Variation
Extending mutation detection to water quality assessment, neurological disorder diagnosis, and agricultural pest control
Obviousness Reasoning
The core detection mechanism remains consistent, with variations representing predictable applications of a known genetic screening technique
Source Patent Element
Targeted therapeutic intervention based on genetic mutation identification
PTD Variation
Developing monitoring and control systems that use mutation detection as a triggering mechanism
Obviousness Reasoning
A skilled practitioner would find it obvious to repurpose mutation detection as a diagnostic and intervention tool across multiple technical domains
Source Patent Element
Precise identification of exon 20 insertion mutations in EGFR
PTD Variation
Creating portable detection devices and integrating machine learning algorithms for enhanced mutation screening
Obviousness Reasoning
Technological enhancement of detection methods through standard engineering approaches represents an obvious improvement to the original diagnostic technique
Source Patent Element
Method of characterizing genetic mutations with specific diagnostic parameters
PTD Variation
Developing cross-domain sensing technologies that leverage mutation detection principles
Obviousness Reasoning
Interdisciplinary application of molecular detection techniques is a predictable evolution for a skilled researcher exploring broader technological implementations
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857513 and the disclosed variations, a person having ordinary skill in the art would find the proposed technical extensions obvious and predictable. The published technical disclosure demonstrates that the core principles of EGFR mutation detection represent a generalizable diagnostic approach that can be systematically adapted across multiple technological domains through routine engineering modifications.

Original Patent Information

Patent NumberUS 11,857,513
TitleSelective inhibitor of exon 20 insertion mutant EGFR
Assignee(s)TAIHO PHARMACEUTICAL CO., LTD.